{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:13:03Z","timestamp":1786993983980,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T00:00:00Z","timestamp":1387238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.maturitas.2013.12.005","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T15:01:23Z","timestamp":1387292483000},"page":"274-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women"],"prefix":"10.1016","volume":"77","author":[{"given":"James","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Portman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"R. Garn","family":"Mabey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2013.12.005_bib0005","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1743-6109.2009.01335.x","article-title":"Prevalence and impact of vaginal symptoms among postmenopausal women","volume":"6","author":"Santoro","year":"2009","journal-title":"J Sex Med"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/jsm.12190","article-title":"Vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) Survey","author":"Kingsberg","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/13697137.2011.647840","article-title":"Vaginal health: Insights, views & attitudes (VIVA) \u2013 results from an international survey","volume":"15","author":"Nappi","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/gme.0b013e31805170eb","article-title":"The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society","volume":"14","author":"The North American Menopause Society","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0025","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1743-6109.2009.01692.x","article-title":"Vulvovaginal atrophy: current and future therapies (CME)","volume":"7","author":"Ibe","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0030","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1743-6109.2011.02543.x","article-title":"To lube or not to lube: experiences and perceptions of lubricant use in women with and without dyspareunia","volume":"9","author":"Sutton","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0035","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/jsm.12022","article-title":"Women's perceptions about lubricant use and vaginal wetness during sexual activities","volume":"10","author":"Jozkowski","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/gme.0b013e31821f92df","article-title":"Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review","volume":"19","author":"Tan","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/gme.0b013e31824b970a","article-title":"The 2012 hormone therapy position statement of: The North American Menopause Society","volume":"19","author":"The North American Menopause Society","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0050","series-title":"Estrace cream [package insert]","year":"2011"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0055","series-title":"Estring [package insert]","year":"2008"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0060","series-title":"Premarin vaginal cream [package insert]","year":"2012"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0065","series-title":"Osphena [package insert]","year":"2013"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0070","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/17425255.2010.487483","article-title":"Pharmacologic evaluation of ospemifene","volume":"6","author":"McCall","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0075","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/endo.141.2.7342","article-title":"Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats","volume":"141","author":"Qu","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/gme.0b013e318223e82a","article-title":"Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model","volume":"19","author":"Burich","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0085","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0960-0760(01)00066-8","article-title":"In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer","volume":"77","author":"Taras","year":"2001","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0378-5122(02)00206-2","article-title":"Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women","volume":"43","author":"Voipio","year":"2002","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0100","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0105","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0110","first-page":"1397","article-title":"Efficacy and safety of daily ospemifene 60mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women (abstract)","volume":"19","author":"Simon","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/gme.0b013e318279ba64","article-title":"Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy","volume":"20","author":"Portman","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/13697130500117946","article-title":"Urogenital effects of selective estrogen receptor modulators: a systematic review","volume":"8","author":"Albertazzi","year":"2005","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1067\/mob.2002.123938","article-title":"Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study","volume":"187","author":"Goldstein","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0130","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0015-0282(99)00113-2","article-title":"Estrogen receptor alpha and beta expression in the vaginal walls and uterosacral ligaments of premenopausal and postmenopausal women","volume":"71","author":"Chen","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0135","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1067\/mob.2001.119627","article-title":"Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women","volume":"185","author":"Gebhart","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0140","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0029-7844(97)00285-8","article-title":"Estrogen and progesterone receptors in the uterosacral ligament","volume":"90","author":"Mokrzycki","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.AOG.0000109429.67671.d1","article-title":"Effect of raloxifene on urinary incontinence: a randomized controlled trial","volume":"103","author":"Waetjen","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0150","first-page":"91","article-title":"Raloxifene effect on frequency of surgery for pelvic floor relaxation","volume":"98","author":"Goldstein","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1067\/mob.2003.374","article-title":"Short-term urogenital effects of raloxifene, tamoxifen, and estrogen","volume":"189","author":"Vardy","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0160","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ajog.2008.01.012","article-title":"Pelvic organ prolapse surgery following hysterectomy on benign indications","volume":"198","author":"Altman","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2013.12.005_bib0165","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0140-6736(07)61635-3","article-title":"Hysterectomy and risk of stress-urinary-incontinence surgery: nationwide cohort study","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512213003770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512213003770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:59:08Z","timestamp":1759913948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512213003770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0378512213003770"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2013.12.005","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2013.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}